NCT01074996

Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers

A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A randomized , open-label, multicenter, phase II study to compare the efficacy of S-1 and S-1 plus Leucovorin as second line treatment on gemcitabine-refractory patients with inoperable or advanced pancreatic cancers，investigate the correlation between efficacy and the expressions of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	S-1	40-60mg bid , days 1-14, every 3 weeks
DRUG	S-1 plus Leucovorin	S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks

Timeline

• Start date: 2010-02-01
• Primary completion: 2013-10-01
• Completion: 2014-07-01
• First posted: 2010-02-24
• Last updated: 2014-01-16

Locations

1 site across 1 country: China